This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Sofie Voet, Ph.D.
Principal Scientist at Argenx
Speaker

Profile

Sofie obtained a PhD in Biochemistry and Biotechnology at the VIB Center for Inflammation Research and University of Ghent (Belgium). She joined argenx in 2019 as a scientist in the R&D team where she soon became a group leader. Strengthened by a team, she identified a potential therapeutic compound applying the SIMPLEā„¢ Antibody platform and as such became an expert in antibody engineering. Over the years she completed the different steps required to develop a therapeutic antibody, from early discovery up to CTA submission.

Agenda Sessions

  • Antibody Engineering to Maximize the Clearance of Abundant Targets

    ,Ā 10:30am